353 related articles for article (PubMed ID: 20141348)
21. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
McKenney JM
Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
[TBL] [Abstract][Full Text] [Related]
22. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
[TBL] [Abstract][Full Text] [Related]
23. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
Zhao XQ; Morse JS; Dowdy AA; Heise N; DeAngelis D; Frohlich J; Chait A; Albers JJ; Brown BG
Am J Cardiol; 2004 Feb; 93(3):307-12. PubMed ID: 14759379
[TBL] [Abstract][Full Text] [Related]
25. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
[TBL] [Abstract][Full Text] [Related]
27. Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
Charland SL; Malone DC
Curr Med Res Opin; 2010 Feb; 26(2):365-75. PubMed ID: 19995326
[TBL] [Abstract][Full Text] [Related]
28. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Lauring B; Dishy V; Luo WL; Laterza O; Patterson J; Cote J; Chao A; Larson P; Gutierrez M; Wagner JA; Lai E
J Clin Pharmacol; 2009 Dec; 49(12):1426-35. PubMed ID: 19833861
[TBL] [Abstract][Full Text] [Related]
29. Niacin-based therapy for dyslipidemia: past evidence and future advances.
Ito MK
Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
[TBL] [Abstract][Full Text] [Related]
30. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
Ballantyne CM; Davidson MH; McKenney J; Keller LH; Bajorunas DR; Karas RH
Am J Cardiol; 2008 May; 101(10):1428-36. PubMed ID: 18471454
[TBL] [Abstract][Full Text] [Related]
32. Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan.
Lin TH; Voon WC; Yen HW; Huang CH; Su HM; Lai WT; Sheu SH
Kaohsiung J Med Sci; 2006 Jun; 22(6):257-65. PubMed ID: 16793562
[TBL] [Abstract][Full Text] [Related]
33. Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
Salgado BJ; Salgado JV; Dos Santos AM; Casulari LA
Minerva Cardioangiol; 2010 Oct; 58(5):531-42. PubMed ID: 20948500
[TBL] [Abstract][Full Text] [Related]
34. Extended-release niacin (nicotinic acid)/laropiprant.
Perry CM
Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
[TBL] [Abstract][Full Text] [Related]
35. Management of dyslipidemia in the high-risk patient.
Stein EA
Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
McKenney JM
Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
[TBL] [Abstract][Full Text] [Related]
38. Niacin's role in the statin era.
Brooks EL; Kuvin JT; Karas RH
Expert Opin Pharmacother; 2010 Oct; 11(14):2291-300. PubMed ID: 20569085
[TBL] [Abstract][Full Text] [Related]
39. Niacin and laropiprant.
Sanyal S; Kuvin JT; Karas RH
Drugs Today (Barc); 2010 Jun; 46(6):371-8. PubMed ID: 20571606
[TBL] [Abstract][Full Text] [Related]
40. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
Farnier M; Chen E; Johnson-Levonas AO; McCrary Sisk C; Mitchel YB
Vasc Health Risk Manag; 2014; 10():279-90. PubMed ID: 24855368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
